Lansoprazole Delayed-Release Orally Disintegrating Tablets — Class III drug recall D-1006-2019
Terminated recall by Teva Pharmaceuticals USA, reported 2019-03-27, distributed nationwide. Subpotent Drug.
| Recall number | D-1006-2019 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Teva Pharmaceuticals USA, North Wales, PA, United States |
| Recall initiated | 2019-03-11 |
| Classified | 2019-03-15 |
| Reported by FDA | 2019-03-27 |
| Terminated | 2019-11-15 |
| Distributed | Nationwide (US) |
| Quantity | 7,081 bottles |
| Reason classes | potency |
| NDC | 00093-3008, 00093-3008-19, 00093-3008-93, 00093-3009, 00093-3009-19, 00093-3009-93 |
| Lot numbers | 25Q002 |
| Expiration dates | 2019-11 |
Product
Lansoprazole Delayed-Release Orally Disintegrating Tablets, 15 mg, 100 tablets (10 blister cards of 10 tablets each), Rx only, Manufactured in Israel By: Teva Pharmaceutical Ind. Ltd. Jerusalem, 9777402, Israel, Manufactured for: Teva Pharmaceuticals USA, Inc. North Wales, PA 19454, NDC 0093-3008-93
Reason for recall
Subpotent Drug.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1006-2019. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.